← Human Trials & Peer-Reviewed Studies
ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock
Plain-language guide to PMID 38637829 (2024): placebo-controlled randomized controlled trial study of Angiotensin II.
Key Facts
- PMID
- 38637829
- Journal
- Critical care (London, England)
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Leisman DE et al. (14 authors)
- DOI
- 10.1186/s13054-024-04910-6
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Angiotensin II.
The researchers sought to assess how pre-admission use of these medications might impact the response to angiotensin-II treatment during vasodilatory shock.
Why It Was Studied
Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blockers (ARB) medications are widely prescribed.
Who Took Part
In a post-hoc subgroup analysis of the randomized, placebo-controlled, Angiotensin Therapy for High Output Shock (ATHOS-3) trial, the researchers compared patients with chronic angiotensin-converting enzyme inhibitor (ACEi) use, and patients with angiotensin receptor blocker (ARB) use, to patients without exposure to either ACEi or ARB.
The primary outcome was mean arterial pressure after 1-h of treatment.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.
A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.
Biological outcomes included baseline RAS biomarkers (renin, angiotensin-I, angiotensin-II, and angiotensin-I/angiotensin-II ratio), and the change in renin from 0 to 3 h.
What Was Measured
Topics PubMed links to this paper include Angiotensin-Converting Enzyme Inhibitors, Angiotensin II, Renin, Angiotensin Receptor Antagonists, Shock and Norepinephrine.
Author keywords: Renin–angiotensin system and Septic.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Angiotensin II.
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2024 (Critical care (London, England)), a journal based in England.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.